Nanologica Ab · OMXSTO:NICA
Nanologica Ab — Q1 2021 Earnings Presentation
19 slides from Nanologica Ab's earnings presentation, Apr 23, 2021
Slide 1: Interim Report Jan-Mar 2021
i) NANOLOGICA INTERIM REPORT JAN - MAR 2021
Slide 2: Summary of the Period
SUMMARY OF THE PERIOD FINANCIAL OVERVIEW SIGNIFICANT EVENTS DURING THE FIRST QUARTER • Test material from upscaling to large-scale production of silica approved Net revenue TSEK 5,622 Net revenue increased by 54 percent to TSEK 5,622 (3,654). • Scientific advisory board within inhalation formed • Co
Slide 3: CEO Comment: Important Milestones Achieved in Both Business Areas
CEO COMMENT IMPORTANT MILESTONES ACHIEVED IN BOTH BUSINESS AREAS Successful upscaling of the production of silica sales organization has also been strengthened by to ton scale advances Nanologica’s position in the recruitment of an SVP Sales and Senior the preparative chromatography field. At the Ad
Slide 4: Operating Income and Result, Investments, Cash Flow and Financial Position
OPERATING INCOME AND RESULT INVESTMENTS, CASH FLOW AND Development. Investments in tangible fixed assets KOMMANDE RAPPORTTILLFÄLLEN amounted to TSEK 1,997 (953) on the closing day. Delårsrapport As per March 31, kvartal 2021,1 cash and cash24equivalents apr 2020 Net revenue for the first quarter amo
Slide 5: Chromatography
CHROMATOGRAPHY Following the successful upscaling, production of In February, an SVP Sales and Senior Advisor for commercial silica for preparative chromatography chromatography was recruited. The position is in ton scale has started and is progressing based in the US and will handle business accord
Slide 6: Drug Development
DRUG DEVELOPMENT ceutical company Zentiva, for the use of the drug candidate NIC-001 is still paused due to the delivery platforms NLAB Silica and NLAB Spiro®. Corona pandemic. The company will give an The aim of the agreement is to future product update regarding the project during the second speci
Slide 7: Effects of COVID-19, the Share and Owners, Share-Based Incentive Programs
ÅRSSTÄMMA KOMMANDE RAPPORTTILLFÄLLEN the work on the company’s study with the drug Årsstämma i Nanologica AB kommer att hållas i Delårsrapport Reporting and kvartal 1 the Swedish 24 apr Accounting Act.2020 The EFFECTS OF COVID-19 candidate NIC-001 is paused. An update on the SHARE-BASED INCENTIVE Re
Slide 8: Assurance about Nanologica AB (publ)
ASSURANCE ABOUT NANOLOGICA AB (publ) The board of directors and the CEO provide their Nanologica manufactures, develops, and assurance that the interim report provides a fair sells nanoporous silica particles for and true overview of the parent company’s and applications within life science. Nanolog
Slide 9: Financial Statements and Notes
FINANCIAL STATEMENTS AND NOTES Statement of comprehensive income 10 Consolidated financial position 10 Consolidated statement of changes of equity 11 Consolidated statement of cashflow 11 Key figures 12 Notes 13 Nanologica Interim Report Jan-Mar 2021 9
Slide 10: Statement of Comprehensive Income and Consolidated Financial Position
2021 2020 2020 2021 2020 2020 Statement of comprehensive income (TSEK) Jan - Mar Jan - Mar Jan - Dec Consolidated financial position (TSEK) Mar 3 1 Mar 3 1 Dec 3 1 Operating income ASSETS Net sales 5 622 3 654 16 135 Change in inventory, finished goods 723 -311 797 Nonc urrent assets Capitalized wor
Slide 11: Financial Position, Changes in Equity and Cash Flows
2021 2020 2020 2021 2020 2020 Consolidated financial position (TSEK) Mar 3 1 Mar 3 1 3 1 Dec Consolidated statement of cash flows (TSEK) Jan - Mar Jan - Mar Jan - Dec O perating ac tivities EQ UITY AND LIABILITIES Operating profit/loss -6 768 -6 032 -19 571 Adjustment for items not affecting cash fl
Slide 12: Key Figures
2021 2020 2020 2020 2020 2020 2019 Key Figures Jan - Mar O c t - Dec Jul - Sep Apr - Jun Jan - Mar Jan-Dec Jan-Dec Net sales (TSEK) 5 622 6 071 2 089 4 321 3 654 16 135 9 227 Operating profit/loss (TSEK) -6 768 -3 648 -5 795 -4 097 -6 032 -19 571 -20 066 Profit/loss before income tax (TSEK) -7 845 -
Slide 13: Notes
and the assumptions made. Areas that are in particular associated with critical judgements and estimates are described in note 3. NOTES New standards, interpretations, and amendments not yet effective There is a number of standards, amendments to standards, and interpretations which have been issued
Slide 14: Notes: Revenue Recognition
performed in accordance with the five-step model specified in IFRS 15. The sale of a license has been assessed to constitute a right-to-use license and thus revenue recognition of this takes place at a given time. Distribution agreement These agreements usually consist of a number of components (pro
Slide 15: Notes: Accounting Principles
differences when they reverse, based on the laws that have been enacted or substantively enacted its intended use. The cost also includes the estimated cost of its dismantlement, removal or at the reporting date. restoration. Additional expenses that qualify for asset recognition are added to the ca
Slide 16: Notes: Financial Instruments
agreement. Right-of-use assets are amortized on a straight-line basis over the shortest of the useful customer losses, and the cost is reported as a sales cost in the income statement. Upon confirmation life of the asset or the lease term. If the group is reasonably certain to exercise a purchase op
Slide 17: Note 4 Segments
Contingent liabilities NOTE 4 SEGMENTS The group provides information on contingent liabilities if there is a possible commitment that is An operating segment is a part of a group that conducts operations from which it can generate confirmed only by several uncertain future events and it is not prob
Slide 18: Note 5 Transition to IFRS
2021 2020 2020 Composition of net sales, region (TSEK) Jan - Mar Jan - Mar Jan - Dec Chromatography 141 694 4 466 Sweden 0 0 319 China 13 532 3 324 USA 0 0 410 Rest of the World 128 163 414 Drug development 5 481 2 960 11 670 Sweden 4 879 2 595 9 718 Rest of the World 602 365 1 952 5 622 3 654 16 13
Slide 19: Nanologica AB contact details
Nanologica AB Forskargatan 20G 151 36 Södertälje 08 410 749 49 info@nanologica.com www.nanologica.com